#science journal

Based on the study provided, here is a summary of sleep efficiency (SE) in individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS):

Key Findings on Sleep Efficiency:

Overall Reduction: Patients with ME/CFS exhibit significantly poorer sleep efficiency compared to healthy controls. They experience a nearly doubled sleep onset latency (taking much longer to fall asleep) and increased wakefulness after sleep onset (frequent waking during the night).

The "Time in Bed" Dissociation: Despite spending nearly an extra hour in bed, the actual total sleep time of ME/CFS patients does not differ from healthy individuals. This demonstrates that prolonged sleep opportunity does not translate into restorative sleep due to their compromised sleep efficiency.

High Night-to-Night Fluctuation: A hallmark finding of this study is that sleep efficiency in ME/CFS is highly unstable and shows pronounced intraindividual variability from one night to the next. Patients frequently alternate between low- and relatively high-efficiency nights.

Preserved Bedtime Schedules: Interestingly, this high instability in sleep continuity occurs despite patients maintaining relatively regular and stable bedtimes, which is often an adaptive pacing strategy to manage their illness.

Clinical Implications

Science Journal

Conclusions

Plate VII. Molar teeth and skulls of Reithrodontomys (North American harvest mice). North American Fauna No. 36. 1914.

AI Summary:

This preprint proposes that tiny particles released by gut microbes, called gut microbiota–derived extracellular vesicles (GMEVs), are a key mechanistic bridge between Long COVID–related gut dysbiosis, leaky gut, systemic inflammation, and neuroinflammation, especially in people with neurological Long COVID symptoms.​

Big-picture findings:

People with Long COVID show persistent, symptom-linked changes in their gut microbiome for at least 12 months, especially those with neurological symptoms such as memory issues and brain fog.​

Transferring stool from women with neurological Long COVID into germ-free mice causes leaky gut, neurobehavioral changes, and activation of astrocytes and microglia in the brain, while stool from Long COVID patients without neurological symptoms does not.

Isolated GMEVs from Long COVID patients trigger inflammation in intestinal epithelial cells, weaken barrier function, activate macrophages, and strongly activate human iPSC-derived microglia in vitro.

Chronic oral dosing of mice with Long COVID–derived GMEVs reshapes their gut microbiota, induces intestinal and systemic inflammation, alters behavior, and activates glial cells in specific brain regions.

AI summary:

Key findings: long COVID

COVID‑19 was linked to a broad spectrum of comorbidities beyond the lungs, including circulatory, nervous, musculoskeletal, digestive, endocrine/metabolic, mental/behavioral, ocular, and oncologic conditions.​

People with substantial pre‑existing multimorbidity—especially cardiovascular disease, diabetes, kidney disease, COPD, and neuropsychiatric disorders—were more likely both to get COVID‑19 and to develop post‑COVID (long COVID) sequelae.​

Key findings: long flu

Influenza showed a similarly broad, system‑spanning pattern of associations, again involving circulatory, neurological, musculoskeletal, digestive, metabolic, mental/behavioral, ocular, respiratory, autoimmune, and cancer endpoints.​

Pre‑existing cardiovascular disease, chronic respiratory disease, type 2 diabetes, and inflammatory disorders strongly predisposed people to clinically significant influenza, indicating infection risk clusters in those with high baseline chronic disease burden.​

Long‑term sequelae and “long flu”

After influenza, there was a durable increase in new‑onset multi‑organ disease, with some risks remaining elevated for up to 5–15 years, defining a clear “long flu” phenotype.​

The most persistent signals were cardiovascular (thromboembolism, major adverse cardiovascular events such as heart failure, atrial fibrillation, myocardial infarction, stroke) and neurological/psychiatric (migraine, dementia/Alzheimer’s, depression), plus metabolic and renal outcomes like new‑onset type 2 diabetes and chronic kidney disease.​

The authors argue that influenza should be seen as a systemic event embedded in a chronic disease continuum, not just an isolated respiratory illness.​

Interpretation and implications

Both infections behave as systemic “stress tests” that unmask and accelerate chronic disease, especially in people with existing cardiometabolic and inflammatory conditions.​